Impression Healthcare Limited announced that it has received all relevant permits for the importation of key cannabinoid constituents of IHL-42X to treat Obstructive Sleep Apnoea (`OSA'). Simultaneously, IHL has commenced sophisticated product formulation development of IHL-42X to be used in upcoming clinical trial activities. Key endpoints being observed in the clinical trial are set in an expanded clinical trial protocol and include the following assessments: Severity of OSA measured by the Apnoea-Hypopnea Index, which is the globally recognised score of OSA severity. Number of Oxygen desaturation episodes that occur during patient nocturnal sleep. Daytime somnolence and cognitive performance - measured by generally accepted neurocognitive tests. A key secondary endpoint includes any influence that the constituents of IHL-42X have on driving the morning after a dose of IHL-42X. This study will be a world first and a driver of project value, which will occur at clinically validated driver testing facilities managed by Swinburne University. Impression has engaged an FDA consultant to commence the FDA registration process. Initial advice is that IHL should apply for registration under an FDA accelerated pathway. Doing so will eliminate the requirement to conduct certain pre-clinical steps due to widely accepted publicly available clinical data on certain constituents of IHL-42X. The accelerated pathway reduces both time and cost over the life of the clinical trial process to registration and marketability.